Continuing medical educationMelanoma in situ: Part II. Histopathology, treatment, and clinical management
Section snippets
Histopathology of melanoma in situ
Key points The histopathologic diagnosis of melanoma in situ can be difficult Immunohistochemical stains may aid in the diagnosis by highlighting junctional melanocytes Microphthalmia transcription factor (MITF) and SOX10 are emerging as the preferred immunohistochemical stains to aid in the diagnosis of melanoma in situ Atypical melanocytic hyperplasia in the setting of sun-damaged skin represents an important diagnostic challenge and can be difficult to differentiate from early melanoma in situ,
Current recommendations and trends in the treatment of melanoma in situ
Key points Excisional margins of 0.5 cm are considered the standard treatment for melanoma in situ, but the lack of randomized controlled trials supporting this standard is noteworthy There is evidence to support wider margins (ranging between 0.5-1.0 cm)
Because of the potential of MIS to transform into malignant melanoma (MM) and the possibility of sampling error in biopsy specimens of larger melanocytic lesions, excision with at least 0.5-cm margins is recommended.10, 11, 12 Based on Surveillance,
Upstaging to malignant melanoma
Key points Based on the literature, a range of 5% to 29% of melanoma in situ cases are upstaged to invasive malignant melanoma after review of the pathology specimen obtained from complete excision Upstaging occurs more frequently after shave biopsy specimens
In a review of the literature, approximately 5% to 29% of MIS lesions actually proved to have at least 1 focus of invasion upon surgical excision. This finding upstaged the initial diagnosis of MIS to MM, but varied widely because of study sample
Treatment: Surgical removal
Key points Surgical removal may be performed by wide local excision, staged excision with expedited permanent sections, or Mohs micrographic surgery Margins of 0.5 to 0.6 cm result in varying clearance rates and wider margins may be necessary for tumor removal
Various surgical options can be used for the treatment of MIS. These include wide local excision (WLE), staged excision, and Mohs micrographic surgery (MMS). WLE aims to remove the clinically apparent tumor and a surrounding margin of normal tissue.
Staged excision
Key points Staged excision is a means of improving margin control through sequential surgical removal of tissue after examination of the edges by pathology using permanent sections Methods of staged excision include the square technique and the spaghetti technique
Occasionally, because of the finding of positive margins after initial excision, additional tissue needs to be removed. Staged surgical excision with permanent section avoids the limitations of removal by MMS, which is an approach that has not yet
Mohs micrographic surgery
Key points Mohs surgery for melanoma in situ has shown variable clearance rates and success Because of the difficulty of accurately visualizing melanocytes on frozen sections, its success is dependent on the skill of the technician and surgeon Immunohistochemical stains have been employed to better delineate melanocytes on frozen sections
In order to preserve tissue in locations where MIS frequently occurs, some have proposed using the Mohs microscopically controlled surgery approach. In this method,
Imiquimod
Key points Imiquimod is not FDA approved for the treatment of melanoma in situ; its use is therefore considered off-label Clearance rates with imiquimod can vary widely
There are several case reports and open-label studies of the use of imiquimod 5% cream for treatment of MIS, LM subtype.55 Imiquimod is an immune response modifier that works by activating Toll-like receptor 7 (TLR-7) and causes a localized immune response at the targeted site(s). It is approved by the US Food and Drug Administration for the
Radiation
Key point There are limited studies on the use of radiation for melanoma in situ
There are a limited number of studies investigating the use of radiation for MIS. Grenz rays and fractionated radiotherapy have varying degrees of success.97, 98 Recurrence rates range from 0% to 20%, and side effects include radiation dermatitis, telangiectasias, hypo- or hyperpigmentation, erythema, and the development of other neoplasms, such as basal and squamous cell carcinoma.98, 99, 100, 101, 102 Radiation therapy is
Laser therapy
Key point Recurrence after laser therapy can be as high as 38%
Several lasers have been used to treat MIS in case reports and case series. These lasers include CO2, Q-switched neodymium-doped yttrium aluminium garnet, Q-switched ruby, argon, and alexandrite. Combinations of these laser modalities have also been tried. The largest case series involved 22 patients treated with the Q-switched neodymium-doped yttrium aluminium garnet laser. Recurrence rates were 23% after a follow-up of <3 months.103 When
References (122)
- et al.
Quantification of melanocytes in sun-damaged skin
J Am Acad Dermatol
(2011) - et al.
Cutaneous melanoma
Lancet
(2005) - et al.
Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology
J Am Acad Dermatol
(2011) - et al.
Reliability of diagnosis of melanoma in situ
Lancet
(2002) - et al.
Cutaneous head and neck melanoma treated with Mohs micrographic surgery
J Am Acad Dermatol
(2005) - et al.
Surgical margins for melanoma in situ
J Am Acad Dermatol
(2012) - et al.
Surgical excision margins for melanoma in situ
J Plast Reconstr Aesthet Surg
(2014) Margin control for lentigo maligna
J Am Acad Dermatol
(1994)- et al.
Usefulness of the staged excision for lentigo maligna and lentigo maligna melanoma: the “square” procedure
J Am Acad Dermatol
(1997) - et al.
The “spaghetti technique”: an alternative to Mohs surgery or staged surgery for problematic lentiginous melanoma (lentigo maligna and acral lentiginous melanoma)
J Am Acad Dermatol
(2011)
Histologic evaluation of lentigo maligna with permanent sections: implications regarding current guidelines
J Am Acad Dermatol
Staged excision for lentigo maligna and lentigo maligna melanoma: A retrospective analysis of 117 cases
J Am Acad Dermatol
Staged excision versus Mohs micrographic surgery for lentigo maligna and lentigo maligna melanoma
J Am Acad Dermatol
The reliability of frozen sections in the evaluation of surgical margins for melanoma
J Am Acad Dermatol
Topical imiquimod treatment of lentigo maligna: clinical and histologic evaluation
J American Acad Dermatol
Amelanotic lentigo maligna managed with topical imiquimod as immunotherapy
J Am Acad Dermatol
A follow-up study to investigate the efficacy of initial treatment of lentigo maligna with surgical excision
Br J Plast Surg
Inhibition of DNA synthesis of melanoma cells by azelaic acid
J Invest Dermatol
Effect of dicarboxylic acids on lentigo maligna
J Invest Dermatol
Treatment of lentigo maligna with tazarotene 0.1% gel
J Am Acad Dermatol
Fractionated radiotherapy of lentigo maligna and lentigo maligna melanoma in 64 patients
J Am Acad Dermatol
Radiation therapy for cutaneous melanoma
Dermatol Clin
Criteria for histopathologic diagnosis of melanoma, 1947-2000: a critique in historical perspective
Dermatopathol Pract Conceptual
Diagnostic utility and comparative immunohistochemical analysis of MITF-1 and SOX10 to distinguish melanoma in situ and actinic keratosis: a clinicopathological and immunohistochemical study of 70 cases
Am J Dermatopathol
Quantitative comparison of MiTF, Melan-A, HMB-45 and Mel-5 in solar lentigines and melanoma in situ
J Cutan Pathol
Nests with numerous SOX10 and MiTF-positive cells in lichenoid inflammation: pseudomelanocytic nests or authentic melanocytic proliferation?
J Cutan Pathol
The density and distribution of melanocytes adjacent to melanoma and nonmelanoma skin cancers
Dermatol Surg
Melanoma in situ versus melanocytic hyperplasia in sun-damaged skin. Assessment of the significance of histopathologic criteria for differential diagnosis
Am J Dermatopathol
Incomplete biopsy of melanocytic lesions can impair the accuracy of pathological diagnosis
Australas J Dermatol
Are en face frozen sections accurate for diagnosing margin status in melanocytic lesions?
Am J Clin Pathol
Management of cutaneous melanoma
N Engl J Med
NCCN guidelines for melanoma
Consensus on the management of malignant melanoma of the skin in The Netherlands. Dutch Melanoma Working Party
Melanoma Res
Diagnosis and management of early melanoma: a consensus view
Semin Surg Oncol
National Institutes of Health Consensus Development Conference Statement on Diagnosis and Treatment of Early Melanoma, January 27-29, 1992
Am J Dermatopathol
Diagnosis and treatment of early melanoma. NIH Consensus Development Conference. January 27-29, 1992
Consens Statement / NIH Consensus Development Conference National Institutes of Health Consensus Development Conference
Cutaneous melanoma in situ: translational evidence from a large population-based study
Oncologist
Variation in the diagnosis, treatment, and management of melanoma in situ: a survey of US dermatologists
Arch Dermatol
Mohs micrographic excision of melanoma using immunostains
Dermatol Surg
Pigmented lesions in actinically damaged skin. Histopathologic comparison of biopsy and excisional specimens
Arch Dermatol
A reappraisal of melanoma in situ
J Dermatol Surg Oncol
The impact of biopsy technique on upstaging, residual disease, and outcome in cutaneous melanoma
Am J Surg
Mohs micrographic surgery for melanoma: a case series, a comparative study of immunostains, an informative case report, and a unique mapping technique
Dermatol Surg
Treatment of cutaneous melanoma of the face by Mohs micrographic surgery
J Cutan Med Surg
Diagnosis and treatment of early melanoma
JAMA
Interventions for melanoma in situ, including lentigo maligna
Cochrane Database Syst Rev
Management of lentigo maligna and lentigo maligna melanoma with staged excision: a 5-year follow-up
Arch Dermatol
Surgical management of melanoma in situ on chronically sun-damaged skin
Cancer Control
Geometric staged excision for the treatment of lentigo maligna and lentigo maligna melanoma: a long-term experience with literature review
Arch Dermatol
Cited by (56)
Topical delivery of nanoemulsions for skin cancer treatment
2023, Applied Materials TodayTopical Calcipotriol Plus Imiquimod Immunotherapy for Nonkeratinocyte Skin Cancers
2023, JID InnovationsNanodelivery systems for cutaneous melanoma treatment
2023, European Journal of Pharmaceutics and BiopharmaceuticsSecond primary malignancies in patients with melanoma in situ: Insights from the surveillance, epidemiology, and end results program
2021, Cancer EpidemiologyCitation Excerpt :Melanoma in situ (MIS) – defined as melanoma limited to the epidermis [3] – accounts for the majority of the increase in melanoma cases [4]. Early detection and excision typically results in an excellent prognosis [5–7]. However, emerging evidence suggests that a diagnosis of MIS is associated with an increased risk of developing a second primary malignancy (SPM) [8–10].
Margins of Melanoma Excision and Modifications to Standards
2020, Surgical Oncology Clinics of North AmericaCitation Excerpt :Furthermore, there is debate surrounding the appropriate surgical margins in certain melanoma subtypes, as well as melanoma in situ. Melanoma in situ, defined as cutaneous melanoma confined to the epidermis, and the most common subtype, lentigo maligna, present treatment challenges owing to the tendency to have ill-defined clinical margins in addition to the often, and yet unpredictable, subclinical extension of atypical melanocytes, potentially several centimeters beyond the clinical margins.28 In patients with contraindications to surgical resection or significant cosmetic concerns owing to tumor location, alternatives include topical therapies (eg, imiquimod) or radiation.
Melanoma on chronically sun-damaged skin: Lentigo maligna and desmoplastic melanoma
2019, Journal of the American Academy of DermatologyCitation Excerpt :Margins might be difficult to delineate because lesion edges can blend with background melanocytic hyperplasia, prompting the recommendation that a control biopsy be taken from a clinically unaffected area.15 The most reproducible feature of LM is proliferation of atypical melanocytes at the dermoepidermal junction with underlying solar elastosis (Fig 5).11,13,51,71-73 DM is defined by desmoplasia, but the diagnostic requirements are controversial.
Funding sources: None.
Conflicts of interest: None declared.
Date of release: August 2015
Expiration date: August 2018